Synpromics is the leading developer of synthetic promoters and provider of gene expression solutions to the Biotech industry.
Synpromics gives researchers, developers and manufacturers unprecedented control of gene expression through proprietary technology that yields highly specific and active synthetic promoters, thus facilitating a competitive IP position for our partners.
Synpromics was founded in 2010 to commercialise proprietary and patent-pending technology, developed by Dr Michael L Roberts, in the emerging field of synthetic biology. This is a highly disruptive technology putting the power to control gene expression in almost any condition of interest into the hands of scientists developing next generation technologies, cell and gene therapy and medicines, and diagnostics.
Traditionally, promoters tend to be based on viral or gene specific endogenous promoters and have a number of constraints that create a huge bottleneck in the development of tools and products in the Biotech industry. This is not surprising as natural promoters have evolved over millennia to regulate gene expression to the precise levels required to elicit a specific physiological function, in a particular cellular environment. Consequently, natural promoters are not best suited to control the expression of genes in the industrial setting of a bioreactor, nor in the environs of a diseased cell, where a particular degree of specificity and optimal therapeutic expression is required.
Synpromics’ designs and develops patentable synthetic promoters that are designed to regulate genes in a highly specific manner. Given that these promoters greatly improve upon the natural promoters on which the entire biotech industry currently relies, there is enormous potential for the company to drive the Biotech industry forward and transform the entire sector.
Synthetic promoters are DNA sequences that do not exist in nature and which are designed to regulate the activity of genes, controlling a gene’s ability to produce its own uniquely encoded protein. Currently, within the biotech industry, naturally occurring promoters are used to drive protein production. However, natural promoters have evolved for biological functions within the context of the organism in question, and as such they were not purpose-designed for applications within the biotech industry. Depending on the promoter and the specific application, natural promoters are not always able to drive a high level of gene expression and may also be lacking in the desired specificity.
Synpromics' Promoters are Novel and Patentable
The technology developed by Synpromics allows for the design of synthetic promoters that are optimally tailored to drive gene expression at the desired level and specificity. The technology leverages any given gene expression profile in any given cell in order to dictate the ultimate synthetic promoter design, and therefore the range of distinct and relevant synthetic promoters that the company can produce is essentially limitless. Importantly, as Synpromics’ promoters are man-made and the DNA sequences do not exist in nature, each one represents invention rather than discovery and hence can be patented, thus allowing the company to generate an extensive and continually expanding portfolio of commercially valuable patents.
Synpromics Ltd has not received any reviews.
Synpromics Ltd has not received any endorsements.